Andere Sprachen Centessa Pharmaceuticals plc

Aktien

A3CQ72

US1523091007

CNTA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 31.05.2024			% 5 Tage	% 1. Jan.
8.63 ^USD	+6.28%		+4.35%	+8.42%

13.05.	Centessa Pharmaceuticals plc meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
24.04.	Börsengehandelte Fonds höher, Aktienfutures vor dem Glockenschlag am Mittwoch uneinheitlich inmitten der Gewinnflut	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge	24.04.
Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS	24.04.
Centessa Pharmaceuticals Eyes $100 Million in ADS Offering	24.04.
Centessa Pharmaceuticals plc Announces Open IND for ORX750	22.04.
Centessa Pharmaceuticals plc Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Centessa Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28.03.
Centessa Pharmaceuticals Insider Sold Shares Worth $607,960, According to a Recent SEC Filing	26.03.
Centessa Pharmaceuticals plc Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2A Study of Serpinpc for the Treatment of Hemophilia	10.12.
AnaptysBio Secures Exclusive License for Centessa's BDCA2 Modulator Antibody Portfolio	27.11.
Anaptysbio, Inc. Enters into License Agreement with Centessa Pharmaceuticals (UK) Limited	27.11.
Centessa Pharmaceuticals' Q3 Loss Narrows	13.11.
Centessa Pharmaceuticals plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.
Centessa Pharmaceuticals plc Announces Dosing of First Subject in Registrational Present-3 Study Evaluating Serpinpc for the Treatment of Hemophilia B with Inhibitors	31.10.23
CENTESSA PHARMACEUTICALS PLC : Morgan Stanley n'est plus négatif sur le dossier	26.10.23
Centessa Pharmaceuticals plc Announces Preclinical Data Supporting Orx750's Potential as A Best-In-Class Oral Ox2r Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders	25.10.23
Centessa Pharmaceuticals plc Announces Executive Appointments	04.10.23
Centessa Pharmaceuticals Insider Sold Shares Worth $235,688, According to a Recent SEC Filing	22.09.23
Transcript : Centessa Pharmaceuticals plc Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 04:15 PM	12.09.23
World Sleep Congress Releases an Abstract Submit by Centessa Pharmaceuticals plc	24.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Centessa Pharmaceuticals plc

Aktien

A3CQ72

US1523091007

CNTA

Andere Sprachen

Filter